Progressing to clinical trial phases based on the promising potential of STING agonists in cancer treatment are several medications, including ADU-S100,726 E7766,729 MK-1454,730 BMS-986301, and SB-1128.731 Preclinical research findings suggest that STING agonists exhibit immunosuppressive properties in certain tumor types. Here, STING1 is linked to neoplasm.